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Abstract
Background: To determine the distribution of Human leukocyte antigen (HLA) class I genotypes in a Ugandan
population of persons with tuberculosis (TB) and establish the relationship between class I HLA types and
Mycobacterium tuberculosis (MTB) disease.
Methods: Blood samples were drawn from HIV negative individuals with active TB and HIV negative household
controls. DNA was extracted from blood samples and HLA typed by the polymerase chain reaction-sequence
specific primer method. The allelic frequencies were determined by direct count.
Results: HLA-A*02, B*15, C*07, C*03, B*58, C*04, A*01, A*74, C*02 and A*30 were the dominant genotypes in this
Ugandan cohort. There were differences in the distribution of HLA types between the individuals with active TB
and the household controls with only HLA-A*03 allele showing a statistically significant difference (p = 0.017 crude;
OR = 6.29 and p = 0.016; OR = 11.67 after adjustment for age). However, after applying the Benjamini and Hochberg
adjustment for multiple comparisons the difference was no longer statistically significant (p = 0.374 and p = 0.176
respectively).
Conclusions: We identified a number of HLA class I alleles in a population from Central Uganda which will enable
us to carry out a functional characterization of CD8+ T-cell mediated immune responses to MTB. Our results do not
show a positive association between the HLA class I alleles and TB in this Ugandan population however the study
sample was too small to draw any firm conclusions about the role of HLA class I alleles and TB development in
Uganda.
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Background
Uganda is among the world’s 22 countries with a high
TB burden [1]. In addition to the high prevalence the
case-finding rate is low and approximately 58 % of
Uganda’s TB cases remain undetected [2]. One of the
reasons for the difficulty in detecting the majority of TB
cases is due to the poor performance characteristics of
diagnostic methods such as sputum smear microscopy,
chest x-rays and tuberculin skin test (TST), that are
available in Uganda [3–5]. Culturing for tubercle bacilli,
although accurate, takes too long. Other rapid and reli-
able tests such as polymerase chain reaction (PCR) and
enzyme-linked immunospot assay (ELISPOT) are un-
available for diagnosis in Uganda, due to their high
costs, their need for expensive equipment and skilled
manpower [3, 6].
Currently, Mycobacterium bovis bacillus Calmette-
Guerin (BCG) is the only TB vaccine available for
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humans, however, despite its widespread use, it is not ef-
fective in providing protection against pulmonary TB
(PTB) in developing countries [7–9]. Human leukocyte
antigens (HLA) are important molecules for the initi-
ation of adaptive immune responses to infectious agents.
HLA diversity plays a crucial role in the host-pathogen
interaction and can affect the rates of disease acquisition
and outcome [10–12]. An individual’s HLA profile can
determine resistance or susceptibility to certain infec-
tious diseases, e.g., Vijaya et al. [13] showed Indian pa-
tients with the HLA-B51 allele were predisposed to PTB
while the HLA-B52 allele conferred protection from
PTB on individuals carrying it [13]. In studies by Kho-
menko et al. [14], the association between TB and HLA-
A, HLA-B and HLA-C varied between different popula-
tions in the Soviet Union although ethnically related
populations showed associations with the same HLA al-
lele [14]. Despite the fact that little significant associ-
ation between HLA class I alleles and MTB
susceptibility has been found, interallelic variations in
the HLA class I locus may still have an impact on im-
mune recognition due to their ability to present different
peptide repertoires and thereby influencing immune rec-
ognition by antigen-specific T-cells. The identification of
HLA alleles in individuals exposed to TB in Uganda as
well as determining which alleles are associated with the
various TB outcomes will help in screening individuals
in high-risk areas in Uganda for susceptibility to TB and
also to predict their resistance to MTB infection or their
progression to active TB. This would inevitably lead to
better clinical management of TB. In addition, the iden-
tification of the common alleles in the Ugandan TB
population will be useful in the development and evalu-
ation of TB vaccines that will effectively work on a
broader range of the high risk individuals in a Ugandan
population. The aim of this study was to determine the
distribution of HLA class I genotypes in a Ugandan
population of persons with TB and to establish the rela-




Blood samples were obtained from HIV negative Ugan-
dan adults (18 years or older) from Kawempe division,
one of the five administrative divisions in Kampala (Cen-
tral Uganda), who presented with PTB (confirmed with
subsequent positive culture) and were the first TB case
identified in the household (index case). Blood samples
were also obtained from HIV negative individuals of any
age who had resided in the household for at least seven
consecutive days during the 3 months prior to the diag-
nosis of TB in the index case and who were TST positive
(household contacts). TST induration ≥10 mm was con-
sidered indicative of latent TB infection.
HLA typing at the HLA-A, HLA-B and HLA-C loci
DNA was extracted from 200ul of the whole blood sam-
ples using an Epicentre MasterPure DNA purification
kit. The quantity and purity of the DNA was determined
by electrophoresis on a 2.5 % agarose gel stained with
ethidium bromide. The DNA was then genotyped for
HLA class I at the loci A, B and C using OneLambda
HLA class I locus A, B and C polymerase chain
reaction-sequence specific primer (PCR-SSP) typing kit
following the manufacturer’s instructions. The PCR
products were analysed by electrophoresis on a 5 %
agarose gel stained with ethidium bromide. Images of
the gels were taken using a UV transilluminator and the
HLA types of the samples were determined by the pres-
ence of bands in appropriate wells. The HLA alleles at
the 2-digit level were assigned according to the patterns
specified by the manufacturer.
Statistics
Baseline characteristics were tested for distributional dif-
ferences between the active TB subjects and the house-
hold contacts using Fisher’s exact test (categorical
variables) and t-test (continuous variables). The HLA al-
leles were counted directly and the allelic frequencies
determined using the formula alleles/(2 x N). Differences
in allelic frequency between groups were presented with
Odds Ratio (OR), 95 % confidence interval (CI) and
tested with Fisher’s exact test. Since age differed between
the two groups the results were recalculated adjusting
for age by means of logistic regression. Adjustment for
multiple testing was performed using the Benjamini-
Hochberg (FDR) method, taking into account the
number of tests performed within each HLA type. All
statistical analyses were performed in R version 3.1.3
(R Foundation for Statistical Computing). The level of




Seventy-seven subjects were included in the study of
which 32 were confirmed TB cases (index cases) and 45
being TST positive household contacts. Fifty-four and a
half percent of the subjects were female with 50 % of the
index cases and 57.8 % of the household contacts being
female. There was no statistically significant difference
in the percentage of male and female subjects between
the two groups (p = 0.643) (Additional file 1: Table S1).
The mean age of all the subjects was 22.7 years with a
mean of 30.8 years (range 18 to 54 years) for index cases
and a mean of 16.9 years (range 1 to 44) for household
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contacts. There was a statistically significant difference
in age between the two groups (p < 0.001) (Additional
file 1: Table S1) therefore age might be considered a
confounding factor in this study. However, previous
studies have shown that after infection children, particu-
larly those under 2 years old, are at the highest risk of
progression to active disease [15, 16] with the lowest risk
in children aged between 5 - 10 years [15, 17]. Adults
aged 65 years and above are at an increased risk of infec-
tion and reactivation of latent TB [18]. Children older
than 10 years showed similar disease outcomes to those
of adults [16].
The population studied resided in Kawempe division
in Kampala district, Central Uganda. Kampala is a melt-
ing pot of tribes from various regions in Uganda that are
categorized into 5 main ethnicities: Eastern Lacustrine
Bantu, Western Lacustrine Bantu, Eastern Nilotic, West-
ern Nilotic and Central Sudanic. Patient samples in-
cluded subjects who self-reported that they belonged to
particular tribes which were then grouped into the fol-
lowing 4 ethnicities: Eastern Lacustrine Bantu (74 %),
Western Lacustrine Bantu (18.2 %), Eastern Nilotic
(3.9 %) and Western Nilotic (3.9 %). None of the sub-
jects reported being Central Sudanic. The majority of
the subjects are Eastern Lacustrine Bantu who are
mainly found in Central and Eastern Uganda. There
were no statistically significant differences between
index cases and household contacts in terms of tribe
(p = 0.984) and ethnicity (p = 0.882) (Additional file 1:
Table S1).
Thus the family based controls used in this study are
appropriate in an urban ethnically heterogenous popula-
tion to reduce confounding factors such as race, ethni-
city and genetic background as well as socioeconomic
factors [19, 20].
Allelic frequencies
There were 16 distinct HLA-A alleles, 24 distinct HLA-B
alleles and 10 distinct HLA-C alleles at the 2-digit repre-
sentation among the 77 subjects. There were a few cases
of ambiguity that arose with some individuals (n = 39)
having more than 2 alternatives to an allele at a locus
(A*02/A*68, A*11/A*15, A*11/A*23, A*23/A*33, A*26/
A*A23, B*41/B*45, B*51/B*53, C*02/C*03/C*15, C*03/
C*04, C*06/C*07, C*06/C*12 and C*08/C*12). This ambi-
guity was possibly due to methodological limitations, i.e.,
similarity in reactivity patterns of the alleles meaning that
the PCR-SSP was unable to distinguish them. (Additional
file 2: Table S2) shows the allelic frequencies of the HLA-
A, HLA-B and HLA-A C loci of the population. HLA-
A*02 (23 %), A*01 and A*74 (both 10 %) were found to be
the most common HLA-A alleles, HLA-B*15 (19 %), B*58
(15 %) and B*42 and B*44 (both 8 %) were found to be the
most common HLA-B alleles and HLA-C*07 (19 %), C*03
(18 %) and C*04 (15 %) were found to be the most com-
mon HLA-C alleles in the study cohort.
Our study identified approximately the same number
of alleles as previous studies conducted on Ugandans
from Kampala by Kijak et al. and Cao et al. but did not
identify several HLA alleles that were identified in Kijak
and/or Cao’s studies (A*25, A*31, A*69, A*31, B*37,
B*38, B*39, B*52, B*55, B*56, B*73, B*82, C*01, C*05 and
C*18) [21, 22]. This may be attributed to the small sam-
ple size in our study as well as due to the different gen-
etic backgrounds for the tested study populations.
However there was a large overlap in the different stud-
ies for the most frequent HLA class I allele: both our
group and the previous mentioned groups identified
HLA-A*02 to be the most common HLA-A allele
present while HLA-B*15 and B*58 were the most preva-
lent HLA-B alleles present. HLA-C also showed a large
overlap between the three different studies with HLA-
C*07 and C*04 always being among the top three most
common alleles. Our study identified the most common
HLA class I alleles in this particular Ugandan population
and this information is important as the HLA combina-
tions vary from individual to individual meaning that
each person has a different response to TB infection.
HLA association
The allelic frequencies differed numerically between the
active TB patients and the household contacts. In the ac-
tive group the following HLA alleles were the most com-
mon: HLA-A*02 (20.31 %), A*03 (12.50 %), A*30
(10.94 %), A*74 (10.94), HLA-B*15 (23.44 %), B*58
(14.06 %) and B*42 (7.81 %) and HLA-C*03 (20.31 %),
C*07 (18.75 %) and C*04 (10.94 %). The following HLA
alleles were most common in the household contacts:
HLA-A*02 (24.44 %), A*01 (12.22 %) and A*74 (10 %),
HLA-B*58 (15.56 %), B*15 (15.56 %) and B*44 (8.89 %)
and C*07 (18.89 %), C*04 (17.78 %), and C*03 (15.56 %).
(Additional file 3: Table S3) shows the allelic frequencies
of the 2 groups and the p values. There was no statisti-
cally significant difference concerning the expression of
different HLA alleles between the two groups except for
the HLA-A*03 allele (12.50 % versus 2.22 %) (p = 0.017;
OR = 6.29, 95 % CI 1.29-30.68) however after Benjamini-
Hochberg (FDR) adjustment p = 0.374. After adjusting
for age between the two groups for the HLA-A*03 allele
p = 0.016; OR = 11.67, 95 % CI 1.58-86.26 and after
Benjamini-Hochberg (FDR) adjustment p = 0.176. Des-
pite the loss of statistical significance, 8out of 32 active
TB patients had the HLA-A*03 allele but only two of
the household contacts out of 45 had the HLA-A*03 al-
lele - this allele needs to be looked further in a study
with a larger sample size before drawing any firm con-
clusions. A study carried out in 1990 showed that A*03
had a positive association with TB in the Kazakh
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although it had no significance in the other Soviet
groups or was not present in their HLA genotype [14].
This same allele had no positive association in Iraqi and
Indian PTB patients [23, 24].
Conclusions
Uganda has one of the highest TB incidences in the
world. A prophylactic vaccine would be more useful
than TB medication in combating the disease. Despite
the small size of the study we have been able to identify
a number of HLA class alleles in a population from Cen-
tral Uganda and this will enable us to carry out the func-
tional characterization of CD8 immune responses to
MTB antigens and this will identify the most effective
MTB antigens in producing protective immune re-
sponses to MTB infection. This information would be
important in the design of a vaccine for TB.
Our results do not show a positive association between
any of the HLA class I alleles identified and TB. How-
ever, a larger study investigating the association between
the HLA-A*03 allele and TB and also trying to identify
other alleles with positive associations to TB would be
beneficial as identifying such high risk individuals and
administering the appropriate interventions would go a
long way towards improving the clinical management of
TB and reducing the spread of TB in the population.
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